DISCUSSION
Prazosin is reported to have peripheral vascular relaxing effects by a combination of post-synaptic alpha blockade and direct action.14) The agent also relieves congestive heart failure by reducing left ventricular filling pressure, and ventricular impedance with augmentation of cardiac output. 15) The first purpose of our study was to investigate the acute cardiocirculatory effects of a single dose of prazosin.
The present results indicate that a sustained reduction in pulmonary arterial pressure accompanied with a significant increase in cardiac output can be achieved. In conclusion, oral prazosin alone possesses both systemic arteriolar and venodilator effects similar to short-acting nitroprusside. 16) These hemodynamic effects appeared within 30min and were maximum at 2 hours, being still maintained at 8 hours following a single oral dose of the drug.
Although there was a decline in systemic blood pressure, heart rate showed no change. These changes of blood pressure and heart rate caused the decline in the double product, and could improve the myocardial oxygen supply-demand relation. The mechanism of the lack of increase in heart rate in these patients is not clear, but, attenuation of augmented sympathetic nervous system activity, by improvement of congestive heart failure, seemed to be one of the most possible mechanisms. This assumption may be supported by the fact that free fatty acid, which is increased by catecholamine,17) was decreased by prazosin.
As prazosin exerts a rapid and prolonged hemodynamic effects, this agent was expected to be beneficial in the long-term vasodilator therapy. And the second purpose of this study was to determine the efficacy of the long-term oral prazosin therapy in patients with chronic refractory heart f ailure.
The present investigation demonstrated that oral prazosin chronically improved heart failure symptoms indicated by lessened fatigue and dyspnea during the long-term ambulant therapy. And this effect was supported by the findings that peripheral venous pressure declined and ET/PEP by carotid pulse recording increased during the administration of the agent.
In patients with mitral stenosis, the reduction of afterload18) and preload may not increase cardiac output, but aggravate heart failure.
The other report19) indicated that nitroglycerin alleviated pulmonary vascular congestion without a change in cardiac index in patients with mitral stenosis.
In our study, a beneficial effect was observed in 1 patient with mitral stenosis (Case No.4); pulmonary arterial diastolic pressure fell from 20 to 18mmHg, but cardiac index increased from 1.81 to 2.15 1/min/M2 after a single dose of prazosin. This beneficial effect in a patient with mitral stenosis may be produced in some cases when pulmonary vascular resistance is pathologically, but reversibly, elevated. 19) Several observers20), 21) have noted that plasma renin activity is not significantly increased with prazosin in hypertensive patients, when compared with the other vasodilator drugs such as hydralazine. On the contrary, our data indicated the increase of plasma renin activity in congestive heart failure by prazosin therapy. Further investigation is necessary to define the effect of prazosin on plasma renin activity in patients with congestive heart failure.
Thus, prazosin possesses sustained nitroprusside-like balanced dilator actions on the systemic arterial and venous systems, and is effective in the ambulatory management of chronic refractory heart failure.
